Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 16,142 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 16,142 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at $445,680.62. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total value of $436,809.10.

Maze Therapeutics Stock Down 1.8%

MAZE stock opened at $27.18 on Friday. The stock has a market capitalization of $1.51 billion, a P/E ratio of -10.79 and a beta of 2.21. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 17.88. Maze Therapeutics, Inc. has a 1-year low of $12.81 and a 1-year high of $53.65. The business has a fifty day moving average price of $27.79 and a 200-day moving average price of $33.03.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting the consensus estimate of ($0.76). Equities analysts forecast that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Institutional Trading of Maze Therapeutics

Hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Maze Therapeutics in the first quarter valued at about $57,000. Goldman Sachs Group Inc. bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $145,000. Rhumbline Advisers bought a new stake in shares of Maze Therapeutics during the 1st quarter valued at about $80,000. Geode Capital Management LLC grew its stake in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after purchasing an additional 18,773 shares during the period. Finally, Legal & General Group Plc increased its position in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MAZE shares. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. Finally, BTIG Research restated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Maze Therapeutics has a consensus rating of “Buy” and a consensus target price of $66.00.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.